Earlier this week, atai Life Sciences announced the launch of PsyProtix, which aims to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD). The atai subsidiary, formed with Duke University biotech spinout Chymia LLC, has licensed work from Duke’s Mood Disorder Precision Medicine Consortium. According to the press release, this group’s work aims to optimize the…


Previous articlePTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with Liam Farquhar
Next articlePT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood